Amgen and Horizon Therapeutics Resolve FTC Lawsuit Clearing Path to Acquisition

Amgen and Horizon Therapeutics announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. The order clears a path forward to closing its planned $27.8-billion takeout of Horizon, the maker of Tepezza (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).

Amgen has stated to the FTC, the courts and the public that it has no reason, ability or intention to bundle Horizon's Tepezza (teprotumumab-trbw) or Krystexxa (pegloticase injection) with any of its products, according to a company news release. The companies anticipate being able to close the acquisition in early fourth-quarter 2023 and look forward to the opportunity to serve patients around the world suffering from rare diseases.